30902-95-5

Upstream product

• 100-02-7 4-nitro-phenol 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 4163-60-4 β-D-galactose peracetate 
• 108-24-7 acetic anhydride 
• 3150-24-1 4-nitrophenyl-β-D-galactopyranoside 
• 3947-62-4 2,3,4,6-tetra-O-acetyl-α/β-D-galactopyranose 
• 1420786-80-6 C₂₉H₂₈O₁₁ 
• 824-78-2 4-nitrophenol sodium salt 
• 10257-28-0 D-Galactose 
• 25878-60-8 D-galactose pentaacetate 
• 7512-17-6 N-Acetyl-D-glucosamine 
• 86520-63-0 2,3,4,6-tetra-O-acetyl-α-galactopyranosyl trichloroacetimidate 
• 572-09-8 acetobromogalactose 
• 3068-32-4 1-bromo-2,3,4,6-tetra-O-acetyl-D-galactopyranose 

Downstream Products

• 3150-24-1 4-nitrophenyl-β-D-galactopyranoside 
• 170940-41-7 Acetic acid (2S,3R,4S,5S,6R)-4,5-diacetoxy-6-acetoxymethyl-2-(4-acetylamino-phenoxy)-tetrahydro-pyran-3-yl ester 
• 42011-36-9 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-aminophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 249512-66-1 Acetic acid (2R,3S,4S,5R,6S)-3,5-diacetoxy-2-acetoxymethyl-6-(4-methyleneamino-phenoxy)-tetrahydro-pyran-4-yl ester 
• 249512-63-8 Acetic acid (2R,3S,4S,5R,6S)-3,5-diacetoxy-2-acetoxymethyl-6-(4-formylamino-phenoxy)-tetrahydro-pyran-4-yl ester 
• 4163-60-4 β-D-galactose peracetate 
• 17042-39-6 p-nitrophenyl 2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside 
• 1381777-82-7 p-(α-azidoacetamido)phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 
• 1381777-83-8 4-[(1,2,3-triazol-4-acetoxymethyl-1-yl)-acetamido]phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 
• 1381777-84-9 4-[(1,2,3-triazol-4-hydroxymethyl-1-yl)-acetamido]phenyl β-D-galactopyranoside 
• 1427462-40-5 5-(-N-(p-O-(2,3,4,6-tetra-O-acetyl-β-D-galactosyl)phenyl)-aminocarbonyl)-2,2'-bipyridine 
• 1427462-44-9 5-(-N-(p-O-(β-D-galactosyl)phenyl)-aminocarbonyl)-2,2'-bipyridine 
• 5094-33-7 p-aminophenyl β-D-galactopyranoside 

Relevant academic research and scientific papers

Nitrogen-containing aromatic ring derivative containing galactose and application thereof

The invention belongs to the technical field of medicines, and relates to a nitrogen-containing aromatic ring derivative containing galactose, application thereof and a pharmaceutical composition containing the compound. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in prevention or treatment of tumors, inflammatory diseases, autoimmune diseases and other diseases, especially tumors.

Copper-mediated O-arylation of lactols with aryl boronic acids

An efficient and novel methodology to access phenolic glycosides has been established by using copper-mediated coupling reaction of aryl boronic acids with hemiacetals. The reaction takes place normally in the presence of Cu(OAc)2 (1.0 equiv.) and pyridine (2.0 equiv.) at 40 °C. This protocol distinguishes itself by wide substrate scope, operational simplicity and giving rise to a myriad of phenolic glycosides in good to excellent yields.

Syntheses and NMR and XRD studies of carbohydrate-ferrocene conjugates

Carbohydrate-ferrocene conjugates were synthesized and showed that the ferrocene entity appeared to be confined to a low volume so that proton NMR spectroscopy revealed 3 to 4 signals for substituted cyclopentadienyl instead of two usually.

Sugar-polyethylene glycol-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine) conjugated compound and preparation method and application thereof

The invention discloses sugar-polyethylene glycol-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine) conjugated compound and a preparation method and application thereof, wherein the sugar-polyethylene glycol-DSPE conjugated compound is prepared by co

Chemo-enzymatic synthesis of p-nitrophenyl β-D-galactofuranosyl disaccharides from Aspergillus sp. fungal-type galactomannan

β-D-Galactofuranose (Galf) is a component of polysaccharides and glycoconjugates. There are few reports about the involvement of galactofuranosyltransferases and galactofuranosidases (Galf-ases) in the synthesis and degradation of galactofuranose-containing glycans. The cell walls of filamentous fungi in the genus Aspergillus include galactofuranose-containing polysaccharides and glycoconjugates, such as O-glycans, N-glycans, and fungal-type galactomannan, which are important for cell wall integrity. In this study, we investigated the synthesis of p-nitrophenyl β-D-galactofuranoside and its disaccharides by chemo-enzymatic methods including use of galactosidase. The key step was selective removal of the concomitant pyranoside by enzymatic hydrolysis to purify p-nitrophenyl β-D-galactofuranoside, a promising substrate for β-D-galactofuranosidase from Streptomyces species.

Development of Pseudomonas aeruginosa Lectin LecA Inhibitor by using Bivalent Galactosides Supported on Polyproline Peptide Scaffolds

LecA is a galactose-binding tetrameric lectin from Pseudomonas aeruginosa involved in infection and biofilm formation. The emergent antibiotic resistance of P. aeruginosa has made LecA a promising pharmaceutical target to treat such infections. To develop LecA inhibitors, we exploit the unique helical structure of polyproline peptides to create a scaffold that controls the galactoside positions to fit their binding sites on LecA. With a modular scaffold design, both the galactoside ligands and the inter-ligand distance can be altered conveniently. We prepared scaffolds with spacings of 9, 18, 27, and 36 ? for ligand conjugation and found that glycopeptides with galactosides ligands three helical turns (27 ?) apart best fit LecA. In addition, we tested different galactose derivatives on the selected scaffold (27 ?) to improve the binding avidity to LecA. The results validate a new multivalent scaffold design and provide useful information for LecA inhibitor development.

Beta-galactosidase-responsive synthetic biomarker for targeted tumor detection

Tumor biomarkers are highly desirable for the screening of patients with a risk of tumor development and progression. Here, we report a beta-galactosidase (β-gal)-responsive acetaminophen (β-GR-APAP) as a synthetic plasma biomarker for targeted tumor detection. Tumor β-gal labeling via the recognition of tumor-related antigen enabled the detection of a tumor using β-GR-APAP.

Diazepinium perchlorate: a neutral catalyst for mild, solvent-free acetylation of carbohydrates and other substances

Diazepinium perchlorate, an essentially neutral organic salt possessing excellent stability, has been found to be well suited for the acetylation of free as well as partially protected sugars, phenols, thiophenols, thiols and other alcohols as well as amines. The diazepinium perchlorate-catalyzed acetylation is mild, organic and solvent-free and leaves acid sensitive protecting groups such as TBDMS/TBDPS/Tr ethers and isopropylidene/benzylidene acetals present on a substrate unaffected. Regioselective hydroxyl protection in partially protected carbohydrate derivatives/polyhydroxylic compounds was possible and was proved to be a convenient time-saving alternative to the conventional synthesis of such compounds. Easy preparation of the catalyst, mild reaction conditions and an environmentally benign protocol are some of the notable features of this reaction. The results obtained on the acetylation of phenols and thiophenols could be rationalized through their local nucleophilicity index obtained from DFT calculations.

Synthetic multivalent ligands for cholera & cholera-like toxins: Protected cyclic neoglycopeptides

Synthesis of a set of novel glycopeptide analogues as potential cholera/cholera-like toxin inhibitors in their protected form is described. They include di-, tri-, tetra- and pentavalent scaffolds. The synthetic steps were achieved using a combination of solvent-free mechanochemical as well as the conventional solution-phase reactions. During the conventional DIC-HOBt-mediated peptide coupling followed for the preparation of certain glycopeptide analogues an interesting in situ Fmoc deprotection was observed which has been demonstrated to hold potential for synthesiszing glycopeptides/neoglycopeptides with extended polyamide chains.

Preparation method of galactose-containing fatty acid derivative and application of preparation method in field of medicine

The invention relates to a novel p-fatty alkylamide phenyl-beta-D-galactoside compound, a preparation method and application, belonging to the technical field of medicine. A structure general formula of the compound is shown in the description, wherein R is selected from (CH2)6CH3, (CH2)10CH3, (CH2)12CH3, (CH2)14CH3, and (CH2)7CH=CH (CH2)7CH3. The compound has stronger inhibitory activity to tumor cells, and can be used for tumor therapies.